References:
- Maitra A, Bhattacharyya S, Mukherjee S, Era N. A rare case of
oxcarbazepine induced Stevens Johnson Syndrome: toxic epidermal
necrosis overlap. International Journal of Basic & Clinical
Pharmacology . 2017;6(2):466-468.
- Beken B, Can C, Örencik A, Can N, Yazıcıoğlu M. Oxcarbazepine-induced
Stevens–Johnson syndrome: a pediatric case report. Oxf Med Case
Reports . 2017;2017(6).
- Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W,
Roujeau J-C. Correlations Between Clinical Patterns and Causes of
Erythema Multiforme Majus, Stevens-Johnson Syndrome, and Toxic
Epidermal Necrolysis: Results of an International Prospective Study.Arch Dermatol . 2002;138(8).
- Devi K, George S, Criton S, Suja V, Sridevi P. Carbamazepine - The
commonest cause of toxic epidermal necrolysis and Stevens-Johnson
syndrome: A study of 7 years. Indian J Dermatol Venereol
Leprol . 2005;71(5):325.
- Guleria VS, Sharda C, Rana T, Sood AK. Oxcarbazepine induced toxic
epidermal necrolysis - a rare case report. Indian Journal of
Pharmacology . 2015;47(4):459.
- Lin L-C, Lai P-C, Yang S-F, Yang R-C. Oxcarbazepine-induced
Stevens-Johnson Syndrome: A Case Report. The Kaohsiung Journal
of Medical Sciences . 2009;25(2):82-86.
- Trivedi BS, Darji NH, Malhotra SD, Patel PR. Antiepileptic
Drugs-induced Stevens–Johnson syndrome: A case Series. J Basic
Clin Pharm . 2016;8(1):42-44.
- Petrova G, Stoimenova A, Dimitrova M, Kamusheva M, Petrova D, Georgiev
O. Assessment of the expectancy, seriousness and severity of adverse
drug reactions reported for chronic obstructive pulmonary disease
therapy. SAGE Open Med . 2017;5.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the
probability of adverse drug reactions. Clinical Pharmacology &
Therapeutics . 1981;30(2):239-245.
- Hartwig SC, Siegel J, Schneider PJ. Preventability and severity
assessment in reporting adverse drug reactions. American journal
of health-system pharmacy : AJHP : official journal of the American
Society of Health-System Pharmacists . 1992;49(9):2229-2232.
- World Health Organization. The use of the WHO-UMC system for
standardized case causality assessment. Uppsala: The Uppsala
Monitoring Centre; 2005.
- Dinulos JGH, Habif TP. Chapter 18: Hypersensitivity Syndromes and
Vasculitis. In: Dinulos JGH, ed. Habif’s Clinical
Dermatology: A Color Guide to Diagnosis and Therapy . Seventh edition.
Philadelphia: Elsevier, 2020:713-747.
- Burks AW, Holgate ST, O’Hehir RE, Bacharier LB, Broide DH, Hershey GK,
Peebles RS. Chapter 77: Drug Allergy. In:SolenskyR,PhillipsEJ, ed. Middleton’s allergy: Principles and practice . Ninth
edition. Amsterdam: Elsevier, 2020:1261-1282.
- Chung W-H, Hung S-I, Yang J-Y, et al. Granulysin is a key mediator for
disseminated keratinocyte death in Stevens-Johnson syndrome and toxic
epidermal necrolysis. Nat Med . 2008;14(12):1343-1350.
- Schmidt D, Elger CE. What is the evidence that oxcarbazepine and
carbamazepine are distinctly different antiepileptic drugs?Epilepsy Behav . 2004;5(5):627-635.